ArticleMolecular oncology2017
Role of Brf1 interaction with ERα, and significance of its overexpression, in human breast cancer.
Article in Molecular oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 45 citations in OpenAlex.
- tRNA-derived fragments (tRFs) as key non-coding players in the tumor transcriptome of colorectal cancer: introducing a new suspect responsible for the remaining unknowns of tumor pathology.Medical oncology (Northwood, London, England) · 2025Review
- Maf1 cooperates with progesterone receptor to repress RNA polymerase III transcription of select tRNAs.Nucleic acids research · 2025Article
- Downregulation of Brf1 Induces Liver Failure and Inhibits Hepatocellular Carcinoma Progression by Promoting Apoptosis.Journal of Cancer · 2024Article
- Canine Somatic Mutations from Whole-Exome Sequencing of B-Cell Lymphomas in Six Canine Breeds-A Preliminary Study.Animals : an open access journal from MDPI · 2023Article
- Selection of tRNA Genes in Human Breast Tumours Varies Substantially between Individuals.Cancers · 2023Article
- BDP1 as a biomarker in serous ovarian cancer.Cancer medicine · 2023Article
- Article
- Widespread association of ERα with RMRP and tRNA genes in MCF-7 cells and breast cancers.Gene · 2022Article
- Characterization of tRNA expression profiles in large offspring syndrome.BMC genomics · 2022Article
- Processing body (P-body) and its mediators in cancer.Molecular and cellular biochemistry · 2022Review
- Article
- New insights on CRISPR/Cas9-based therapy for breast Cancer.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2021Review
- Exploring the Role and Mechanism of pAMPKOxidative medicine and cellular longevity · 2021Article
- Role of tRNAs in Breast Cancer Regulation.Advances in experimental medicine and biology · 2021Review
- ROS Signaling-Mediated Novel Biological Targets: Brf1 and RNA Pol III Genes.Oxidative medicine and cellular longevity · 2021Review
- Riddle of the Sphinx: Emerging Role of Transfer RNAs in Human Cancer.Frontiers in pharmacology · 2021Review
- Oncostatin M expression andAging · 2020Article
- RNA polymerase III transcription as a disease factor.Genes & development · 2020Review
- Role of betaine in inhibiting the induction of RNA Pol III gene transcription and cell growth caused by alcohol.Chemico-biological interactions · 2020Article
- The significance of Runx2 mediating alcohol-induced Brf1 expression and RNA Pol III gene transcription.Chemico-biological interactions · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
TFIIB-related factor 1 (Brf1) modulates the transcription of RNA Pol III genes (polymerase-dependent genes). Upregulation of Pol III genes enhances tRNA and 5S RNA production and increases the translational capacity of cells to promote cell transformation and tumor development. However, the significance of Brf1 overexpression in human breast cancer (HBC) remains to be investigated. Here, we investigate whether Brf1 expression is increased in the samples of HBC, and we explore its molecular mechanism and the significance of Brf1 expression in HBC. Two hundred and eighteen samples of HBC were collected to determine Brf1 expression by cytological and molecular biological approaches. We utilized colocalization, coimmunoprecipitation, and chromatin immunoprecipitation methods to explore the interaction of Brf1 with estrogen receptor alpha (ERα). We determined how Brf1 and ERα modulate Pol III genes. The results indicated that Brf1 is overexpressed in most cases of HBC, which is associated with an ER-positive status. The survival period of the cases with high Brf1 expression is significantly longer than those with low levels of Brf1 after hormone treatment. ERα mediates Brf1 expression. Brf1 and ERα are colocalized in the nucleus. These results indicate an interaction between Brf1 and ERα, which synergistically regulates the transcription of Pol III genes. Inhibition of ERα by its siRNA or tamoxifen reduces cellular levels of Brf1 and Pol III gene expression and decreases the rate of colony formation of breast cancer cells. Together, these studies demonstrate that Brf1 is a good biomarker for the diagnosis and prognosis of HBC. This interaction of Brf1 with ERα and Brf1 itself are potential therapeutic targets for this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.